...受体酷氨酸激酶活性,由细胞外的配体结合区域和细胞内的酷氨激酶活性区域组成,EGFR的小分子抑制剂(tyrosine kinase inhibitor,TKI)Gefitinib和Erlotinib,与EGFR的细胞内酷氨酸激酶活性区域可逆的结合导致激酶失活,...
基于6个网页-相关网页
...酷氨酸激酶活性,由细胞外的配体结合区域和细胞内的酷氨激酶活性区域组成,EGFR的小分子抑制剂(tyrosine kinase inhibitor,TKI)Gefitinib和Erlotinib,与EGFR的细胞内酷氨酸激酶活性区域可逆的结合导致激酶失活,...
基于3个网页-相关网页
激酶区的小分子抑制剂 Tyrosine Kinase Inhibitor ; TKI
该小组目前正在肝癌动物模型中验证LSF的小分子抑制剂,作为可能的治疗方法。
The team is currently testing small molecule inhibitors of LSF as a possible therapy for HCC in animal models.
介绍了最近几年来关于酪氨酸蛋白磷酸酯酶1B作用的机制以及通过各种途径发现的结构新颖的小分子抑制剂的构效关系研究进展。
The advances made in the new compounds identified as Protein Tyrosine Phosphatases 1B (PTP1B) inhibitors recently and their structure-activity relationship were reviewed in this paper.
据彼得森,小分子抑制剂如ipa - 3等,是很有希望的发现药物的工具。
According to Peterson, small molecule inhibitors such as IPA-3, are promising tools for drug discovery.
应用推荐